21 citations
,
January 2015 in “The Journal of Steroid Biochemistry and Molecular Biology” Progesterone byproduct 5αP stimulates mammary tumor growth, but finasteride can suppress it.
215 citations
,
November 2006 in “Journal of The American Academy of Dermatology” Dutasteride more effective for hair growth, but has more side effects than finasteride.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
66 citations
,
June 2013 in “Journal of Dermatological Treatment” Finasteride and dutasteride effectively treat hair loss, but may cause side effects like sexual dysfunction and depression.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.
40 citations
,
March 2016 in “The Journal of Clinical Endocrinology & Metabolism” Young girls whose mothers have PCOS may have higher activity of a specific enzyme that could lead to developing PCOS later.
39 citations
,
April 2007 in “Therapeutic Drug Monitoring” Finasteride affects urinary steroid profiles and can potentially hide steroid abuse in sports drug testing.
33 citations
,
April 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5α reductase inhibitors treat hair loss but may cause sexual side effects and risks.
23 citations
,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.